Adjunctive brexpiprazole: A review in major depressive disorder

CNS Drugs

Volumn 30, Issue 2, 2016, Pages 91-99

  McKeage, Kate ^a  

^a Mairangi Bay   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BREXPIPRAZOLE; ANTIDEPRESSANT AGENT; QUINOLONE DERIVATIVE; THIOPHENE DERIVATIVE;

DEPRESSION; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; MAJOR DEPRESSION; OPEN STUDY; PHARMACODYNAMIC PARAMETERS; PHARMACOKINETIC PARAMETERS; PHASE 3 CLINICAL TRIAL (TOPIC); POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; COMBINATION DRUG THERAPY; DEPRESSIVE DISORDER, MAJOR; PROCEDURES;

ANTIDEPRESSIVE AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; DEPRESSIVE DISORDER, MAJOR; DRUG THERAPY, COMBINATION; HUMANS; QUINOLONES; THIOPHENES;

EID: 84959916961     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-016-0320-0     Document Type: Review

References (35)

1. National Insititute of Mental Health. Major depression among adults. 2015. http://www.nimh.nih.gov. Accessed 9 Dec 2015.
2. Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry. 2003;64:1465-75.
3. Culpepper L, Muskin PR, Stahl SM. Major depressive disorder: understanding the significance of residual symptoms and balancing efficacy with tolerability. Am J Med. 2015;128:S1-15.
4. Patkar AA, Pae C-U. Atypical antipsychotic augmentation strategies in the context of guideline-based care for the treatment of major depressive disorder. CNS Drugs. 2013;27(Suppl 1):S29-37.
5. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382:951-62.
6. Citrome L. A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach. CNS Drugs. 2013;27(11):879-911.
7. Ginovart N, Kapur S. Role of doapmine D(2) receptors for antipsychotic activity. In: Gross G, Geyer MA, editors. Handbook of experimental pharmacology 212. Current antipsychotics. Munich: Springer; 2012. p. 27-52.
8. Citrome L, Stensbol TB, Maeda K. The preclinical profile of brexpiprazole: what is its clinical relevance for the treatment of psychiatric disorders? Expert Rev Neurother. 2015;15:1219-29.
9. Maeda K, Sugino H, Akazawa H, et al. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 2014;350:589-604.
10. Maeda K, Lerdrup L, Sugino H, et al. Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 2014;350(3):605-14.
11. Oosterhof CA, El Mansari M, Blier P. Acute effects of brexpiprazole on serotonin, dopamine, and norepinephrine systems: an in vivo electrophysiologic characterization. J Pharmacol Exp Ther. 2014;351(3):585-95.
12. Yoshimi N, Futamura T, Hashimoto K. Improvement of dizocilpine-induced social recognition deficits in mice by brexpiprazole, a novel serotonin-dopamine activity modulator. Eur Neuropsychopharmacol. 2015;25(3):356-64.
13. Yoshimi N, Fujita Y, Ohgi Y, et al. Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT1A receptors. Pharmacol Biochem Behav. 2014;124(Suppl C):245-9.
14. Oosterhof CA, El Mansari M, Bundgaard C, et al. Brexpiprazole alters monoaminergic systems following repeated administration: an in vivo electrophysiological study. Int J Neuropsychopharmacol. 2015. doi: 10.1093/ijnp/pyv111.
15. ® (brexpiprazole tablets). 2015. http://www.accessdata.fda.gov/. Accessed 9 Dec 2015.
16. Lerdrup L, Arnt J, Maeda K, et al. Brexpiprazole reduces impulsive behaviour of rats in a delayed discounting test and 5-choice-serial-reaction-time-test [abstract no. 733]. Biol Psychiatry. 2015;77(9 Suppl 1):273S-4S.
17. Lerdrup L, Maeda K, Bundgaard C, et al. Brexpiprazole shows antidepressant-and anxiolytic-like effects in the rat forced swim and Vogel conflict tests [abstract]. In: Annual Meeting of the Society of Biological Psychiatry; 2015.
18. Thase ME, Youakim JM, Skuban A, et al. Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study. J Clin Psychiatry. 2015;76:1232-40.
19. Thase ME, Youakim JM, Skuban A, et al. Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants. J Clin Psychiatry. 2015;76:1224-31.
20. Citrome L. Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2015;69(9):978-97.
21. Fava M, Weiller E, Zhang P, et al. Adjunctive brexpiprazole (OPC-34712) on depressive symptoms in patients with irritability: results from post-hoc analyses [abstract no. 35 plus poster]. In: American Society of Clinical Psychopharmacology Annual Meeting; 2015.
22. McIntyre RS, Zhang P, Weiss C. Effect of adjunctive brexpiprazole (Opc-34712) on depressive symptoms in patients with symptoms of anxious distress: results from post-hoc analyses [abstract no. 55]. In: 168th Annual Meeting of the American Psychiatric Association; 2015.
23. Fava M, Menard F, Davidson CK, et al. Adjunctive brexpiprazole (OPC-34712) in patients with major depressive disorder and irritability: an exploratory study [abstract no. 52 plus poster]. In: American Society of Clinical Psychopharmacology Annual Meeting; 2015.
24. Davis LL, Ota A, Perry P, et al. Adjunctive brexpiprazole (OPC-34712) in patients with major depressive disorder and anxiety symptoms: an exploratory study [abstract no. 177 and poster]. In: 70th Society of Biological Psychiatry Annual Scientific Meeting; 2015.
25. Krystal A, Mittoux A, Meisels P, et al. Adjunctive brexpiprazole (OPC-34712) in patients with major depressive disorder and sleep disturbances: an exploratory study [abstract no. 173]. Biol Psychiatry. 2015;77(9 Suppl 1):64S-5S.
26. Baker RA, Okame T, Perry P, et al. Switching from inadequate adjunctive treatment options to brexpiprazole adjunctive to antidepressant: an open-label study on the effects on depressive symptoms and cognitive and physical functioning [abstract no. 53]. In: American Society of Clinical Psychopharmacology Annual Meeting; 2015.
27. Weisler R, Ota A, Perry P, et al. Adjunctive brexpiprazole (OPC-34712) in young patients with MDD who are working or at school: an exploratory study [abstract no. 54]. In: American Society of Clinical Psychopharmacology Annual Meeting; 2015.
28. Nelson JC, Skuban A, Zhang P. Long-term safety of adjunctive brexpiprazole (OPC-34712) in MDD: results from two 52-week open-label studies [abstract no. 57]. In: 168th Annual Meeting of the American Psychiatric Association; 2015.
29. Weiss C, Skuban A, Hobart M, et al. Incidence, onset, duration and severity of akathisia with adjunctive brexpiprazole (OPC-34712) in major depressive disorder: analysis of two pivotal studies [abstract no. 66 plus poster]. In: American Society of Clinical Psychopharmacology Annual Meeting; 2015.
30. Nelson C, Skuban A, Hobart M, et al. The metabolic tolerability profile of adjunct brexpiprazole in major depressive disorder [abstract no. 61 plus poster]. In: American Society of Clinical Psychopharmacology Annual Meeting; 2015.
31. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder, third edition. 2010. http://psychiatryonline.org. Accessed 3 Dec 2015.
32. Spielmans GI, Berman MI, Linardatos E, et al. Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes. PLoS Med. 2013;10:e1001403.
33. Marcus RN, McQuade RD, Carson WH, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2008;28:156-65.
34. Citrome L, Ota A, Nagamizu K, et al. The effect of brexpiprazole (OPC-34712) versus aripiprazole in adult patients with acute schizophrenia: an exploratory study [abstract no. 560]. In: 70th Society of Biological Psychiatry Annual Meeting; 2015.
35. US National Institutes of Health. Clinical Trials.gov. 2015. https://clinicaltrials.gov/. Accessed 18 Nov 2015.